55 withdrawn. 55 Phase 1, 24 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 55 | Withdrawn 55 |
| Phase 2 | 24 | Withdrawn 24 |
Follow Pneumonia: new trials by email Literature Review of Pneumonia trials Research Report on Pneumonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Use of hUC-MSC Product (BX-U001) for the Treatment of COVID-19 With ARDS Human umbilical cord mesenchymal stem cells + best supportive care, Placebo control + best supportive care - COVID-19, ARDS | Phase 1 / Phase 2 | Withdrawn | Baylx Inc. | 2026-06-01 | 2025-12-29 | |
| A Study on 2 Different Combination Tablets of Nirmatrelvir Plus Ritonavir to Compare Them With Marketed Paxlovid in Healthy Participants Paxlovid, Nirmatrelvir/ritonavir - Biological Availability, Healthy Participants | Phase 1 | Withdrawn | Pfizer | 2025-08-15 | 2025-12-26 | |
| A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose - COVID-19 | Phase 1 | Withdrawn | BioNTech SE | 2025-01-06 | 2024-03-18 | |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline - Covid19, Postviral Syndrome | Phase 1 / Phase 2 | Withdrawn | Direct Biologics, LLC | 2024-11-01 | 2024-11-22 | |
| Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Allogeneic Mesenchymal Stromal Cells - COVID-19 Pneumonia, Viral Pneumonia | Phase 1 | Withdrawn | Medical University of South Carolina | 2024-10-01 | 2024-10-30 | |
| Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents Recombinant COVID-19 vaccine (Sf9 cells), Placebo control - COVID-19 | Phase 1 / Phase 2 | Withdrawn | WestVac Biopharma Co., Ltd. | 2024-07-01 | 2025-03-28 | |
| GS-441524 for COVID-19 SAD, FE, and MAD Study in Healthy Subjects GS-441524, Placebo - COVID-19 | Phase 1 | Withdrawn | National Center for Advancing Translational Sciences (NCATS) | 2024-06-15 | 2025-02-14 | |
| A Phase 1, Randomised, Double-blinded, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of RH109 as Booster Lyophilized COVID-19 mRNA Vaccine, Sodium chloride - COVID-19 Pandemic | Phase 1 | Withdrawn | Wuhan Rhegen Biotechnology Co., Ltd. | 2023-06-01 | 2023-07-14 | |
| Simvastatin Nasal Rinses for the Treatment of COVID-19 Mediated Dysomsia Simvastatin - Olfactory Disorder, COVID-19 | Phase 1 | Withdrawn | Washington University School of Medicine | 2023-05-01 | 2023-06-12 | |
| Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant VBI-2901e - COVID-19, Coronavirus Infections | Phase 1 | Withdrawn | VBI Vaccines Inc. | 2023-03-01 | 2023-04-04 | |
| A Phase I/II Study of GLB-COV2-043 as a COVID-19 Vaccine Booster GLB-COV2-043, BNT162b2/COMIRNATY® - COVID-19 | Phase 1 / Phase 2 | Withdrawn | GreenLight Biosciences, Inc. | 2023-02-21 | 2023-08-14 | |
| Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults AV-COVID-19 - COVID-19 | Phase 1 / Phase 2 | Withdrawn | Aivita Biomedical, Inc. | 2023-01-01 | 2023-05-03 | |
| CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 DeltaRex-G - COVID-19, Cytokine Storm | Phase 1 / Phase 2 | Withdrawn | Aveni Foundation | 2022-12-12 | 2025-02-24 | |
| Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients ASC10, Placebo - SARS CoV 2 Infection | Phase 1 | Withdrawn | Ascletis Pharmaceuticals Co., Ltd. | 2022-11-28 | 2024-11-01 | |
| Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers INO-4800, INO-9112, CELLECTRA® 2000 - Coronavirus Infection | Phase 1 | Withdrawn | Inovio Pharmaceuticals | 2022-10-01 | 2022-11-17 | |
| Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19 UCMSCs, Placebo - COVID-19, Acute Respiratory Distress Syndrome | Phase 1 | Withdrawn | Joshua M Hare | 2022-10-01 | 2022-05-12 | |
| Safety, Reactogenicity, and Immunogenicity Study of a Lyophilized COVID-19 mRNA Vaccine A Lyophilized COVID-19 mRNA Vaccine, Placebo - COVID-19 Pandemic | Phase 1 | Withdrawn | Wuhan Recogen Biotechnology Co., Ltd. | 2022-07-01 | 2023-04-27 | |
| Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19. Mesenchymal stem cell, Placebo - COVID-19 Pneumonia, COVID-19 | Phase 1 / Phase 2 | Withdrawn | Paulo Brofman | 2022-05-01 | 2025-02-10 | |
| Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants. [14C]PF-07321332 - Healthy Participants | Phase 1 | Withdrawn | Pfizer | 2022-02-22 | 2022-01-31 | |
| A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines. UB-612 - COVID-19 | Phase 1 | Withdrawn | United Biomedical Inc., Asia | 2022-02-15 | 2022-08-26 |
Showing 20 of 55. Sign in to see all of them.
COVID-19 (52) · Respiratory Distress Syndrome (7) · Coronavirus Infections (6) · Respiratory Insufficiency (3) · Acute Lung Injury (2) · Severe Acute Respiratory Syndrome (2) · Cytokine Release Syndrome (1) · Dyspnea (1) · Hemostatic Disorders (1) · Hypertension, Pulmonary (1) · Hypoxia (1) · Lung Diseases (1) · Lung Injury (1) · Pneumonia, Aspiration (1)
Infections (55) · Respiratory Tract Infections (55) · Lung Diseases (54) · Respiratory Tract Diseases (54) · Coronaviridae Infections (52) · Nidovirales Infections (52) · RNA Virus Infections (52) · Virus Diseases (52) · Pneumonia, Viral (51) · Coronavirus Infections (46) · Respiration Disorders (10) · Pathological Conditions, Signs and Symptoms (4) · Cardiovascular Diseases (2) · Lung Injury (2)
STI-2020 (3) · Sodium Chloride (3) · Sirolimus (2) · 1-(nitrosooxy)propan-2-ol and 2-(nitrosooxy)propan-1-ol drug combination (1) · 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide (1) · AV-COVID-19 vaccine (1) · Abatacept (1) · Azithromycin (1) · BNT162 Vaccine (1) · Blood Specimen Collection (1) · GS-441524 (1) · Hydroxychloroquine (1) · Injections (1) · KPNA1 protein, human (1) · Minerals (1)
Sorrento Therapeutics, Inc. (3) · Stanford University (3) · ImmunityBio, Inc. (2) · Massachusetts General Hospital (2) · Pfizer (2) · Washington University School of Medicine (2) · Aivita Biomedical, Inc. (1) · Ascletis Pharmaceuticals Co., Ltd. (1) · Attgeno AB (1) · Aveni Foundation (1) · Bausch Health Americas, Inc. (1) · Baylx Inc. (1) · Beth Israel Deaconess Medical Center (1) · Bio-Thera Solutions (1) · BioNTech SE (1)
United States (16) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Israel (1) · Sweden (1)
Mike Royal, MD (3) · Kevin V Grimes, MD (2) · Lorenzo Berra, MD (2) · Alpesh Amin, MD (1) · Anya Loncaric (1) · Arya Mani, MD (1) · Bill Arana (1) · Cecilia Kemi, PhD (1) · Chang-Yi Wang, Ph.D. (1) · Charlie Strange, MD (1) · Dean L Kellogg, MD, PhD (1) · Douglas W Losordo, MD (1) · Esther Yoon, MD (1)